Kun Ping Lu (卢坤平), MD, PhD

Kun Ping Lu (卢坤平), MD, PhD

Professor, Harvard Medical School; Chief, Division of Translational Therapeutics, Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center
Associate Member, Broad Institute of MIT and Harvard
Research Interests : Pin1; cis-trans proline isomerase; phosphorylation signaling; protein conformation regulation; cancer; Alzheimer’s disease; brain injury; autoimmune disease
Lukunping
Kun Ping Lu received his medical, graduate and postdoctoral training at Fujian Medical University, Duke University and Salk Institute, respectively. He became an independent investigator and rose through the ranks to be tenured Professor at Harvard Medical School and Chief of Division of Translational Therapeutics at Department of Medicine and Cancer Center at Beth Israel Deaconess Medical Center. Working with Xiao Zhen Zhou, he discovered Pin1-catalyzed prolyl isomerization as a novel post-phosphorylation signaling mechanism in health and disease, having the opposite effect on cancer and Alzheimer’s disease, two major aging diseases that were rarely studied together before. Their current focuses are to elucidate cis-trans conformational changes in disease development, and to develop Pin1-targeted therapies, including Pin1 inhibitors to block multiple cancer-driving pathways and eliminate cancer stem cells, and cis P-tau antibody to neutralize a major early driver of neurodegeneration in Alzheimer’s and brain injury.  His honors include Leukemia and Lymphoma Society of America Scholar (1998), Pew Scholar in Biomedical Sciences (1999), Young Investigator Award from Chinese Biological Investigator Society (1999), Elected Member of American Society for Clinical Investigation (2007), Elected Fellow of American Association for Advancement of Science (2012), and Elected Member of Association of American Physicians (2013).

Contact Information

Center for Life Science, Room 0408, 3 Blackfan Circle, Boston, MA  02115
p: 617-735-2016